AOBiome

AOBiome

AOBiome Therapeutics is a therapeutics company, based in Newton, Massachusetts and founded in 2013, that conducts clinal-stage research to address inflammatory conditions with Ammonia Oxidizing Bacteria (AOB).

AOBiome is a biotechnology company headquartered in Newton, Massachusetts that was founded in 2013 by David Whitlock, James Heywood, Spiros Jamas

is conducting clinical trials for treatments for acne, eczema, rosacea, allergic rhinitis, hypertension and migraine and the company is in preclinical stages in pulmonary and gut research. The company focuses on Ammonia Oxidizing Bacteria (AOB), which consumes nitric oxide (NO) and nitrite, a key signaling molecule in the circulatory system, central nervous system and as a systemic response in the human body.

AOB metabolism lowers pH and affects the microbiome, anti-inflammatory and vasodilatory compounds. The company claims that AOB correlates with a reduction in populations of Staphylococcus aureus and Propionibacterium acnes which are associated with eczema and acne.

AOBiome has a proprietary strain of AOB called B244 which is a strain of Nitrosomonas eutropha administered live in different potencies and formulations. In early 2019 AOBiome was issued a patent for the use of their AOB for treating eczema. The Phase 2 clinical trial for this treatment is expected to be complete in 2019. AOB treatment for acne has completed Phase 2 and Phase 3 is planned for 2019.

AOBiome invented an AOB spray containing a bacteria commonly found in dirt and untreated water called Nitrosomonas eutropha. The company produces microbiome-friendly products under the name Mother Dirt such as face and body cleanser and shampoo that clean the skin without killing AOB.

Funding

Seed

On March 21, 2013 AOBiome completed their seed funding round with $630,000 in funding from undisclosed investors.

Series A

On August 28, 2014 AOBiome completed their series A funding round with $576,500 in funding from undisclosed investors.

Series B

On December 31, 2014 AOBiome completed their series B funding round with $7.5 million in funding from Wakestream Ventures and Hedgewood.

Series C

On January 5, 2017 AOBiome completed their series C funding round with $30 million in funding from ICarbonX.

Timeline

January 5, 2017

Series C funding round

On January 5, 2017 AOBiome completed their series C funding round with $30 million in funding from ICarbonX.

December 31, 2014

Series B funding round

On December 31, 2014 AOBiome completed their series B funding round with $7.5 million in funding from Wakestream Ventures and Hedgewood.

August 28, 2014

Series A funding round

On August 28, 2014 AOBiome completed their series A funding round with $576,500 in funding from undisclosed investors.

March 21, 2013

Seed funding round

On March 21, 2013 AOBiome completed their seed funding round with $630,000 in funding from undisclosed investors.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
AOBiome Funding Round 2017
30,000,000
January 5, 2017
5 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Alex Goddard

VP of Research and Development

Christine Mason

Advisor

David Whitlock

Inventor and Founder

Dr. Judith Ng Cashin

Chief Medical Officer

Jasmina Aganovic

Employee

Jesse Rasch

Investor

Jim Hoffman

SVP of Stragegic Alliances and Communications

John Durant

Advisor

Lauren Ambrogeo

Chief Operating Officer

Ramesh Ratan

CFO and SVP of Manufacturing

Spiros Jamas

SVP of Therapeutic Development

Todd Krueger

President, CEO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.